|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9511220D0
(en)
*
|
1995-06-02 |
1995-07-26 |
Glaxo Group Ltd |
Solid dispersions
|
|
US5874440A
(en)
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
|
US6060477A
(en)
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
|
US6046216A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
|
GB9514464D0
(en)
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
DE69711882T2
(de)
|
1996-05-10 |
2002-10-31 |
Icos Corp., Bothell |
Carbolinderivate
|
|
US6331543B1
(en)
*
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US6071934A
(en)
|
1997-03-25 |
2000-06-06 |
Cell Pathways, Inc. |
Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
|
|
ATE315931T1
(de)
|
1997-06-23 |
2006-02-15 |
Cellegy Pharma Inc |
Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
|
|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
|
IL132406A0
(en)
*
|
1998-10-21 |
2001-03-19 |
Pfizer Prod Inc |
Treatment of bph with cgmp elevators
|
|
US6133271A
(en)
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
US6211220B1
(en)
|
1998-11-23 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6420410B1
(en)
|
1998-11-24 |
2002-07-16 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
US6358992B1
(en)
|
1998-11-25 |
2002-03-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with indole derivatives
|
|
ATE256466T1
(de)
|
1999-03-24 |
2004-01-15 |
Harbor Branch Oceanographic |
Verwendung von manzaminen als entzündungshemmende mittel
|
|
IL135817A0
(en)
*
|
1999-04-30 |
2001-05-20 |
Lilly Icos Llc |
Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
|
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
ATE399554T1
(de)
|
1999-08-03 |
2008-07-15 |
Lilly Icos Llc |
Pharmazeutische zusammensetzung enthaltend tadalafil
|
|
US6821975B1
(en)
|
1999-08-03 |
2004-11-23 |
Lilly Icos Llc |
Beta-carboline drug products
|
|
PL357522A1
(en)
|
1999-10-11 |
2004-07-26 |
Pfizer, Inc. |
5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
|
|
TW200400821A
(en)
*
|
1999-11-02 |
2004-01-16 |
Pfizer |
Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
|
|
US6562830B1
(en)
|
1999-11-09 |
2003-05-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
|
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
AU5584901A
(en)
|
2000-04-19 |
2001-10-30 |
Icos Corp |
Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
|
|
UA74826C2
(en)
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
WO2001094345A2
(en)
|
2000-06-07 |
2001-12-13 |
Lilly Icos Llc |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
|
ATE333457T1
(de)
*
|
2000-06-23 |
2006-08-15 |
Lilly Icos Llc |
Zyklische gmp-spezifische phosphodiesteraseinhibitoren
|
|
WO2002000656A2
(en)
*
|
2000-06-23 |
2002-01-03 |
Lilly Icos Llc |
Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
|
|
AU2001266575A1
(en)
|
2000-06-26 |
2002-01-08 |
Lilly Icos Llc |
Chemical compounds
|
|
PL360081A1
(en)
*
|
2000-07-24 |
2004-09-06 |
Bayer Cropscience Ag |
Biphenyl carboxamides
|
|
EP1305313A1
(en)
*
|
2000-08-02 |
2003-05-02 |
Lilly Icos LLC |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
MXPA03002909A
(es)
|
2000-10-02 |
2003-09-10 |
Lilly Icos Llc |
Compuestos quimicos.
|
|
WO2002028858A2
(en)
*
|
2000-10-02 |
2002-04-11 |
Lilly Icos Llc |
Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
|
EP1211313A3
(en)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation of PDE11A activity
|
|
AU2002211493A1
(en)
|
2000-11-06 |
2002-05-15 |
Lilly Icos Llc |
Indole derivatives as pde5-inhibitors
|
|
ATE348101T1
(de)
*
|
2001-04-25 |
2007-01-15 |
Lilly Icos Llc |
Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion
|
|
FR2824829B1
(fr)
*
|
2001-05-16 |
2005-06-03 |
Macef |
Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
|
|
CA2445625C
(en)
*
|
2001-06-05 |
2010-07-27 |
Lilly Icos Llc |
Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives
|
|
CA2445460A1
(en)
*
|
2001-06-05 |
2002-12-12 |
Lilly Icos Llc |
Carboline derivatives as pde-5 inhibitors
|
|
MXPA03011080A
(es)
*
|
2001-06-05 |
2004-07-08 |
Lilly Icos Llc |
Compuestos tetraciclicos como inhibidores de pde5.
|
|
DE60213798T2
(de)
|
2001-06-21 |
2007-08-16 |
Lilly Icos Llc, Wilmington |
Carbolinderivate als pdev inhibitoren
|
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
|
JP2005509038A
(ja)
*
|
2001-11-09 |
2005-04-07 |
シェーリング コーポレイション |
多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
|
|
CN1280292C
(zh)
*
|
2001-11-14 |
2006-10-18 |
奥索-麦克尼尔药品公司 |
用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
EP1506015A2
(en)
*
|
2002-05-23 |
2005-02-16 |
Pfizer Limited |
Pharmaceutical combination of pde5 inhibitors with ace inhibitors
|
|
SI1509525T1
(sl)
|
2002-05-31 |
2006-12-31 |
Schering Corp |
Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
|
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
|
DE60324949D1
(de)
*
|
2002-07-31 |
2009-01-08 |
Lilly Icos Llc |
Modifizierte pictet-spengler-reaktion und damit hergestellte verbindungen
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
KR20050085563A
(ko)
|
2002-12-13 |
2005-08-29 |
워너-램버트 캄파니 엘엘씨 |
하부요로증상을 치료하기 위한 알파-2-델타 리간드
|
|
EP1624893A2
(en)
|
2003-04-01 |
2006-02-15 |
Applied Research Systems ARS Holding N.V. |
Inhibitors of phosphodiesterases in infertility
|
|
ES2326119T3
(es)
|
2003-04-29 |
2009-10-01 |
Pfizer Inc. |
5,7-diaminopirazolo(4,3-d)pirimidinas utiles en el tratamiento de la hipertension.
|
|
NZ544040A
(en)
*
|
2003-05-22 |
2009-03-31 |
Nycomed Gmbh |
Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
|
|
EP1644021B1
(en)
*
|
2003-06-13 |
2012-08-22 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
ES2427166T3
(es)
*
|
2003-06-23 |
2013-10-29 |
Ono Pharmaceutical Co., Ltd. |
Compuesto heterocíclico tricíclico novedoso
|
|
US7291640B2
(en)
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
JP2007514665A
(ja)
*
|
2003-12-12 |
2007-06-07 |
ミオゲン インコーポレイティッド |
エノキシモン製剤ならびに心肥大および心不全の治療へのそれらの使用方法
|
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
|
JP2007518788A
(ja)
|
2004-01-22 |
2007-07-12 |
ファイザー・インク |
バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
|
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
|
US20060025463A1
(en)
*
|
2004-03-22 |
2006-02-02 |
Michael Bristow |
Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
|
|
JP2007530566A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
JP2007532526A
(ja)
|
2004-04-07 |
2007-11-15 |
ファイザー・インク |
ピラゾロ［４，３−ｄ］ピリミジン類
|
|
WO2005116030A1
(en)
*
|
2004-05-31 |
2005-12-08 |
Matrix Laboratories Ltd |
A process for the preparation of tadalafil
|
|
WO2006007213A1
(en)
*
|
2004-06-23 |
2006-01-19 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
|
WO2006049986A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Dr. Reddy's Laboratories Ltd. |
Polymorphic forms of tadalafil
|
|
US20060111571A1
(en)
*
|
2004-11-02 |
2006-05-25 |
Shlomit Wizel |
Tadalafil crystal forms and processes for preparing them
|
|
AR051780A1
(es)
*
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
PL1829874T3
(pl)
|
2004-12-22 |
2014-07-31 |
Ono Pharmaceutical Co |
Tricykliczny związek i jego zastosowanie
|
|
JP2008520751A
(ja)
*
|
2005-02-25 |
2008-06-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
大粒子サイズを有するタダラフィル及びそれを調製する方法
|
|
JP2008527012A
(ja)
*
|
2005-02-25 |
2008-07-24 |
テバ ファーマシューティカル インダストリーズ リミティド |
タダラフィルの精製法
|
|
WO2006091975A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Process of synthesizing tadalafil
|
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
|
MX2007012607A
(es)
*
|
2005-04-12 |
2008-01-11 |
Teva Pharma |
Preparacion de intermedios de tadalafil.
|
|
SI2366393T1
(sl)
|
2005-04-19 |
2013-12-31 |
Takeda Gmbh |
Roflumilast za zdravljenje pljučne hipertenzije
|
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
|
EA012577B1
(ru)
|
2005-05-12 |
2009-10-30 |
Пфайзер Инк. |
БЕЗВОДНЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[1-(2-ЭТОКСИЭТИЛ)-5-(N-ЭТИЛ-N-МЕТИЛАМИНО)-7-(4-МЕТИЛПИРИДИН-2-ИЛАМИНО)-1Н-ПИРАЗОЛО[4,3-d]ПИРИМИДИН-3-КАРБОНИЛ]МЕТАНСУЛЬФОНАМИДА
|
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
|
BRPI0615972A2
(pt)
*
|
2005-07-29 |
2011-05-31 |
Concert Pharmaceuticals Inc |
composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
|
|
US7863274B2
(en)
*
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
|
JP2009503020A
(ja)
|
2005-08-03 |
2009-01-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
肥満症の治療におけるフリバンセリンの使用
|
|
US7678363B2
(en)
|
2005-08-26 |
2010-03-16 |
Braincells Inc |
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
CA2622200A1
(en)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
|
US20070237822A1
(en)
|
2005-10-12 |
2007-10-11 |
Ramana Malladi |
Testosterone gel and method of use
|
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
EP1945214A1
(en)
|
2005-10-29 |
2008-07-23 |
Boehringer Ingelheim International GmbH |
Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
|
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
WO2007100387A2
(en)
*
|
2005-11-03 |
2007-09-07 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing tadalafil
|
|
US8067433B2
(en)
|
2005-11-09 |
2011-11-29 |
Zalicus Inc. |
Methods, compositions, and kits for the treatment of ophthalmic disorders
|
|
US7202229B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
US7201929B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
WO2007104035A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
EP2004644A1
(en)
*
|
2006-03-24 |
2008-12-24 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of tadalafil
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
CA2651862A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US20090291958A1
(en)
*
|
2006-06-08 |
2009-11-26 |
Auspex Pharmaceuticals, Inc. |
Substituted PDE5 inhibitors
|
|
EP2037927B1
(en)
|
2006-06-30 |
2010-01-27 |
Boehringer Ingelheim International GmbH |
Flibanserin for the treatment of urinary incontinence and related diseases
|
|
EP1875914A1
(en)
*
|
2006-07-07 |
2008-01-09 |
Teva Pharmaceutical Industries Ltd. |
Solid compositions comprising tadalafil and at least one carrier
|
|
PL2046292T3
(pl)
|
2006-07-21 |
2010-08-31 |
Novartis Ag |
Preparaty eterów benzymidazolilo-pirydylowych
|
|
AU2007286288A1
(en)
|
2006-08-14 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Formulations of flibanserin and method for manufacturing the same
|
|
IL197129A
(en)
|
2006-08-25 |
2014-08-31 |
Boehringer Ingelheim Int |
Controlled release system and method for production
|
|
AR062501A1
(es)
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
|
US7998971B2
(en)
*
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
WO2008036678A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
|
PT2101777E
(pt)
|
2006-12-12 |
2015-09-18 |
Gilead Sciences Inc |
Composição para tratar uma hipertensão pulmonar
|
|
WO2008095136A2
(en)
|
2007-01-31 |
2008-08-07 |
Henkin Robert I |
Methods for detection of biological substances
|
|
CA2677690C
(en)
*
|
2007-02-12 |
2012-05-15 |
James V. Winkler |
Treatment of comorbid premature ejaculation and erectile dysfunction
|
|
JP5550101B2
(ja)
|
2007-02-12 |
2014-07-16 |
ヴィリックス ファーマシューティカルズ インコーポレイテッド |
トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法
|
|
WO2008103470A2
(en)
*
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
MX2009011588A
(es)
*
|
2007-04-25 |
2009-11-05 |
Teva Pharma |
Formas de dosificacion solidas que comprenden tadalafil.
|
|
FR2916200A1
(fr)
*
|
2007-05-18 |
2008-11-21 |
Fourtillan Snc |
Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
|
|
DE102007028869A1
(de)
*
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
HRP20120686T1
(hr)
|
2007-06-29 |
2012-09-30 |
Ranbaxy Laboratories Limited |
Postupak priprave intermedijera tricikličkih spojeva
|
|
EP2033962A1
(en)
*
|
2007-08-22 |
2009-03-11 |
4Sc Ag |
Tetracyclic indolopyridines as EG5 inhibitors
|
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
|
WO2009091777A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
ITMI20080285A1
(it)
*
|
2008-02-22 |
2009-08-23 |
Endura Spa |
Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
|
|
EP2107059A1
(en)
*
|
2008-03-31 |
2009-10-07 |
LEK Pharmaceuticals D.D. |
Conversion of tryptophan into ß-carboline derivatives
|
|
PL385356A1
(pl)
|
2008-06-03 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania tadalafilu
|
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
EP2181997A1
(en)
|
2008-10-30 |
2010-05-05 |
Chemo Ibérica, S.A. |
A process for the preparation of tadalafil
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
JP2012513464A
(ja)
|
2008-12-23 |
2012-06-14 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
ホスホジエステラーゼ阻害剤及びその使用
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
US8586587B2
(en)
|
2009-02-26 |
2013-11-19 |
Thar Pharmaceuticals, Inc. |
Crystalline molecular complex of tadalafil and methylparaben
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
|
CN102970965A
(zh)
|
2010-04-05 |
2013-03-13 |
Sk化学公司 |
含有pde5抑制剂的减少皮肤皱纹的合成物
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
BR112013008983A2
(pt)
|
2010-10-15 |
2016-07-05 |
Gilead Sciences Inc |
composições e métodos de tratamento da hipertensão pulmonar
|
|
JP5816704B2
(ja)
|
2011-02-10 |
2015-11-18 |
インテルキム、ソシエダッド アノニマ |
テトラヒドロ−β−カルボリンから誘導される化合物を得る方法
|
|
WO2012107092A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
|
WO2012107090A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Granulated composition comprising tadalafil and a disintegrant
|
|
WO2012107541A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
|
US20120123124A1
(en)
*
|
2011-04-22 |
2012-05-17 |
Drug Process Licensing Associates, LLC |
Manufacturing process for Tadalafil from racemic or L-tryptophan
|
|
CN102180876B
(zh)
*
|
2011-05-28 |
2016-05-18 |
浙江华海药业股份有限公司 |
一种他达那非晶型i的制备方法
|
|
EP2535049A1
(en)
|
2011-06-17 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Tadalafil for the treatment of dementia
|
|
CN102367253B
(zh)
*
|
2011-09-20 |
2016-04-06 |
浙江华海药业股份有限公司 |
一种制备他达拉非晶型a的方法
|
|
WO2013067309A1
(en)
|
2011-11-04 |
2013-05-10 |
Xion Pharmaceutical Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
WO2013109227A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical compositions comprising ceftibuten
|
|
WO2013109223A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
WO2014092661A1
(en)
|
2012-01-18 |
2014-06-19 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
CN104168895B
(zh)
|
2012-02-28 |
2020-02-21 |
首尔制药株式会社 |
包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
|
|
US20150297601A1
(en)
|
2012-10-05 |
2015-10-22 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
CN105025900B
(zh)
|
2012-12-04 |
2018-11-02 |
株式会社阿丽浱欧 |
包含5型磷酸二酯酶抑制剂的神经细胞的细胞凋亡抑制用组合物
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
ES2700989T3
(es)
|
2012-12-21 |
2019-02-20 |
Mayo Found Medical Education & Res |
Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
|
|
KR20150119871A
(ko)
|
2013-02-21 |
2015-10-26 |
아드베리오 파마 게엠베하 |
메틸 ｛4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리디노-3-일]피리미디노-5-일｝메틸 카르바메이트의 형태
|
|
CN103232451A
(zh)
*
|
2013-05-14 |
2013-08-07 |
张家港威胜生物医药有限公司 |
一种他达那非的简易制备工艺
|
|
US10899756B2
(en)
|
2013-07-17 |
2021-01-26 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
WO2015089105A1
(en)
|
2013-12-09 |
2015-06-18 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
|
EP3108245B1
(en)
|
2014-02-18 |
2020-07-22 |
Robert I. Henkin |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
|
AR099416A1
(es)
|
2014-02-28 |
2016-07-20 |
Lilly Co Eli |
Terapia combinada para la hipertensión resistente
|
|
JP6687550B2
(ja)
|
2014-06-23 |
2020-04-22 |
セルジーン コーポレイション |
肝疾患又は肝機能異常を治療するためのアプレミラスト
|
|
EP2962684A1
(en)
|
2014-06-30 |
2016-01-06 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally disintegrating formulations of tadalafil
|
|
EP2962685B1
(en)
|
2014-06-30 |
2020-01-08 |
Montero Gida Sanayi Ve Ticaret A.S. |
Orally disintegrating formulations of tadalafil
|
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
|
EP3172207B1
(en)
|
2014-07-23 |
2019-03-06 |
KRKA, d.d., Novo mesto |
A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
EP3301095B1
(en)
*
|
2015-06-26 |
2019-12-04 |
Chongqing Dikang Erle Pharma Co. Ltd. |
Novel phosphodiesterase type-5 inhibitor and application thereof
|
|
CN105541840B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
关键中间体及其合成方法和在制备他达拉非方面的应用
|
|
CN105541835B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
|
|
RU2019121646A
(ru)
|
2016-12-14 |
2021-01-15 |
Респира Терапьютикс, Инк. |
Способы и композиции для лечения легочной гипертензии и других заболеваний легких
|
|
CN106977516B
(zh)
*
|
2017-03-02 |
2019-06-18 |
山东裕欣药业有限公司 |
一种他达拉非的制备方法
|
|
KR20210150495A
(ko)
|
2019-04-10 |
2021-12-10 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
|
|
RU2692764C1
(ru)
|
2019-04-26 |
2019-06-27 |
Общество с ограниченной ответственностью "Балтфарма" |
Способ получения тадалафила
|
|
CN111995658B
(zh)
*
|
2019-05-27 |
2022-08-02 |
首都医科大学 |
Ldv修饰的五环哌嗪二酮及其制备和应用
|
|
CA3144770A1
(en)
|
2019-07-15 |
2021-01-21 |
Biolab Sanus Farmaceutica Ltda |
Stereoisomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indol-3-yl)-6,7-dihydro-3h-oxazol[3,4-a]pyrazine-5,8-dione and use thereof as an antitumor agent and phosphodiesterase enzyme inhibitor
|
|
CN110606847A
(zh)
*
|
2019-07-30 |
2019-12-24 |
中国医药集团总公司四川抗菌素工业研究所 |
一种他达拉非顺式中间体的制备方法及其应用
|
|
US11590209B2
(en)
|
2020-01-21 |
2023-02-28 |
Palatin Technologies, Inc. |
Use of bremelanotide in patients with controlled hypertension
|
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|
|
CN120641103A
(zh)
|
2023-01-25 |
2025-09-12 |
阿丽派欧株式会社 |
包含5型磷酸二酯酶抑制剂作为有效成分用于预防或治疗创伤后应激障碍的组合物
|
|
AU2024220563A1
(en)
|
2023-02-16 |
2025-08-14 |
University Of Rochester |
Improving glymphatic-lymphatic efflux
|
|
CN116715667A
(zh)
*
|
2023-06-20 |
2023-09-08 |
常州制药厂有限公司 |
一种他达拉非新晶型b及其制备方法
|
|
EP4684777A1
(en)
|
2024-07-24 |
2026-01-28 |
Adalvo Limited |
A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione
|